Pharmacy Times®
Specialty Pharmacy Times
  • Will Right-to-Try Laws Enhance the Importance of Specialty Pharmacy Counseling?
  • OIG Releases Report on Medicare Part B Drug Price Data
  • Valued Services from Specialty Pharmacy: A Manufacturers Perspective
  • Who Is the Customer in Specialty?
  • How Will Specialty Pharmacy Be Affected By Cost Containment?
  • Specialty Pharmacies Help Patients Manage Immune Globulin Care
Targeted Drug Ineffective in Treatment of Early Stage Lung Cancer
Davy James, Associate Editor
Patients with early stage tumors fare worse with erlotinib than if they take nothing.
Ebola Continues to Spread Among Health Care Workers
Davy James, Associate Editor
Large increase reported in number of African health care workers infected with virus.
Anti-Cancer Drug Effective Against Stem Cell Transplant Complications
Davy James, Associate Editor
Bortezomib found to effectively treat chronic graft-versus-host disease.
Cyramza by Eli Lilly
Michael R. Page, PharmD, RPh
Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.
Zontivity by Merck and Co, Inc
Michael R. Page, PharmD, RPh
The FDA has approved Zontivity (voraxapar) for prevention of thrombotic cardiovascular events in patients with peripheral artery disease or a history of myocardial infarction.
Featured Video
Charting the Course for Mid-Size Specialty Pharmacy
Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services discusses the future path of the company.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        October 2014        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.